Cumberland Pharmaceuticals (CPIX) Reports Q3 Loss of $0.11
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/14/2026
- Wall St set for muted open as Middle East tensions curb risk appetite
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
Cumberland Pharmaceuticals Reports Third Quarter 2024 Financial Results and Company Update
November 7, 2024 4:05 PM EST       New Real World Study of 150,000 Patients Favors Caldolor over ketorolac Â
       DMD Program Receives FDA Orphan Drug & Rare Pediatric Disease Designations Â
NASHVILLE, Tenn., Nov. 7, 2024 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (Nasdaq: CPIX), a specialty pharmaceutical company, today announced that its portfolio of FDA-approved brands delivered combined revenues of $9.1 million during the third quarter of 2024. The company ended the third quarter of 2024 with $77 million in total assets, $52 million in... More
